LeMaitre Vascular (LMAT) Earnings Date & Reports

Key Takeaways

• LeMaitre Vascular (NASDAQ: LMAT) is scheduled to report Q2 2026 results on August 4, 2026, after the market close.
• Company guidance calls for Q2 EPS of $0.79–$0.84 (midpoint $0.81), representing roughly 35% growth versus the $0.60 reported in Q2 2025.
• Revenue is guided to a range of $70.5 million to $72.5 million, implying approximately 11% organic growth year over year.
• Gross margin expansion remains a central theme, with Q2 guidance set at 72.1% following a standout 72.7% in Q1 2026.
• Analyst consensus stands at EPS of $0.81 on revenue of approximately $71.5 million, squarely aligned with the midpoint of management's guidance.
• The stock has pulled back roughly 12% from its 52-week high of $118.01, placing added focus on whether a strong print can reinvigorate upside momentum.

Earnings Context and Why It Matters

LeMaitre Vascular's Q2 2026 report arrives at a time when the company is delivering some of the strongest operating leverage in its peer group. The Burlington, Massachusetts-based maker of vascular devices and implants — used primarily by vascular surgeons to treat peripheral vascular disease — has been compounding double-digit revenue growth with even faster profit expansion. In Q1 2026, sales rose 11% while operating income surged 41% and diluted earnings per share (EPS) jumped 42%. With the stock trading at roughly 34 times forward earnings and down from its 52-week high, this report will test whether LeMaitre's premium valuation can be sustained by its margin trajectory. Investors will also be watching for any revisions to full-year 2026 guidance, which currently calls for $280 million in revenue and adjusted EPS of $3.00.

Earnings Expectations

Management's official Q2 2026 guidance, issued alongside Q1 results on May 5, projects sales between $70.5 million and $72.5 million, gross margin of 72.1%, operating income of $20.8 million to $22.3 million, and diluted EPS of $0.79 to $0.84. At the midpoint, revenue of $71.5 million would represent 11% organic growth and EPS of $0.81 would mark a 35% increase from the $0.60 reported in the second quarter of 2025.

Consensus analyst estimates, according to data from MarketBeat and TipRanks, align closely with the midpoint of management's guidance at $0.81 in EPS and roughly $71.5 million in revenue. This tight alignment between guidance and consensus leaves relatively little room for error. LeMaitre has beaten Wall Street estimates in each of the last four quarters, with surprises ranging from 1.5% to 8.8%. However, the stock's post-earnings reactions have been mixed: shares rose 24.4% after the Q4 2025 report in February but declined 1.6% after the Q1 2026 beat in May, suggesting that the market has already priced in much of the operational momentum.

Key metrics to watch beyond the headline numbers include organic revenue growth by product category — grafts, valvulotomes, and carotid shunts have been standout performers — and geographic segment performance, particularly in EMEA (Europe, Middle East, and Africa), where sales grew 29% in Q1 2026. Investors will also monitor average selling price (ASP) trends, which have been a significant driver of gross margin expansion alongside manufacturing efficiencies.

AI Screener

For investors tracking earnings season and looking to identify stocks with strong fundamental and technical profiles, Tickeron's AI Screener offers a powerful way to cut through the noise. The AI Screener is an AI-driven stock and ETF discovery tool that allows traders and investors to filter thousands of securities using customizable criteria such as industry, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. Rather than manually scanning markets, users can surface breakout candidates, trending stocks, and trade ideas aligned with their strategy. Whether you want to track medical device companies ahead of earnings or identify bullish technical setups in any sector, the AI Screener helps you do it more efficiently.

Market Reaction and Investor Sentiment

Sentiment heading into the Q2 2026 print appears cautiously optimistic but tempered by the stock's recent price action. After reaching an all-time high of $118.01 earlier in 2026, shares of LMAT have retreated to approximately $103, reflecting a pullback of roughly 12%. The stock remains up approximately 28% year to date, but the three-month return shows a decline of roughly 5%, indicating that some of the post-Q4 2025 euphoria has faded.

Analyst ratings reflect a "Moderate Buy" consensus, with price targets averaging around $112.60, suggesting roughly 10% upside from current levels. However, Zacks Research downgraded the stock from "strong-buy" to "hold" in early July, and several other firms maintain "equal weight" or "hold" ratings. Short interest stands at approximately 6.4% of the float, which is notable and could fuel a short squeeze if results exceed expectations. Institutional ownership remains high at roughly 85%, signaling strong professional conviction in the long-term story, but the elevated short interest suggests a segment of the market expects near-term disappointment.

Forward Outlook and Key Factors to Monitor

Beyond the Q2 headline numbers, investors should pay close attention to any updates on full-year 2026 guidance. During the Q1 earnings call, management raised annual gross margin guidance to 72.3% and increased operating income and EPS targets. A reaffirmation or further upgrade would reinforce the operating leverage narrative that has underpinned the stock's premium valuation.

One area of particular interest is the company's sales force expansion. LeMaitre ended Q1 2026 with 158 sales representatives and plans to grow that number to between 170 and 180 by year-end. Commentary on hiring progress and rep productivity will offer clues about the pace of future revenue growth. Additionally, the international business — especially in EMEA and APAC (Asia-Pacific) — has been a critical growth engine, and investors will want to hear whether that momentum is continuing.

On the product side, the Artegraft biologic graft line and the company's valvulotome and carotid shunt categories have been primary growth drivers. Any updates on competitive dynamics, regulatory developments, or supply chain conditions will matter. The company has also signaled continued interest in mergers and acquisitions (M&A), and with approximately $367 million in cash and securities on the balance sheet as of Q1 2026, LeMaitre has ample firepower for bolt-on deals that could accelerate growth.

Finally, cost trends bear watching. While gross margin expansion has been impressive, driven by higher ASPs and manufacturing efficiencies, sustained margin gains will depend on the company's ability to maintain pricing discipline and contain operating expense growth, which has been running at a moderate pace relative to revenue. The Q2 operating margin is guided to 30% at the midpoint, and delivering at or above that level would mark another quarter of best-in-class profitability for the medical device sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations